Biobijou
Biobiage homepages, K-viewy, Kviewt, KOreA Cosmetic, Pilgrims, beauty products, global biobias, medical devices, cosmics.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | KRW1.5b Valuation: KRW150.0b | Early VC | |
| Total Funding | 000k | ||
Biobijou Co., Ltd. is a medical aesthetics company that has demonstrated a swift trajectory from its inception to becoming a publicly traded entity. Founded on July 12, 2018, by CEO Yang Jun-ho, the company initially operated under the name JJ Medical Co., Ltd. before rebranding to Biobijou in November 2019. A significant milestone was achieved in May 2025, when the company was listed on the KOSDAQ market, following a successful IPO that confirmed its offering price at the top of its band.
The company operates on a vertically integrated business model, managing the entire value chain from in-house research and development to manufacturing, sales, and marketing. This comprehensive control allows Biobijou to maintain price competitiveness, a key factor in its strategy, which is supported by manufacturing process automation and direct sourcing of raw materials. The business is heavily export-oriented, with a significant focus on the global market from its early days. In 2024, exports accounted for 80% of its business, with the Chinese market being a primary target, contributing 68% of total sales. The company has established a sales network spanning over 21 countries across Asia, Europe, and other regions.
Biobijou's product portfolio is centered on medical and aesthetic devices, primarily skin boosters and hyaluronic acid (HA) fillers, which constituted approximately 49% and 23% of sales in 2024, respectively. Key product brands include COLENA, CANDORLOV, LIMELUCE, MIWELL, and ELLELUX. The company's HA fillers are noted for their stability, with a three-year shelf life, and the manufacturing process is designed to minimize impurities. Biobijou leverages its proprietary technologies, holding multiple patents for manufacturing methods and equipment that enhance product efficacy in areas like moisturization, whitening, and wrinkle improvement. Revenue for 2024 reached 29.6 billion KRW, with an operating profit of 8.2 billion KRW.
Keywords: medical aesthetics, hyaluronic acid fillers, skin boosters, K-beauty, aesthetic medicine, cosmetic dermatology, injectable dermal fillers, anti-aging treatments, skincare manufacturing, global beauty market, KOSDAQ listed, Yang Jun-ho, aesthetic product development, pharmaceutical wholesaler, beauty biotechnology, COLENA, CANDORLOV, MIWELL, non-surgical aesthetics, cosmetic export